Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

“Samples were sparse, the TV ads were late ... says Alkermes is working to develop an inhaled insulin with partner Eli Lilly, in Indianapolis, that is called AIR Insulin and is currently ...

We recently compiled a list of the Jim Cramer Discussed These 11 Stocks Before The DeepSeek Sell-Off. In this article, we are ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... market launch with a new commercial leader.

In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...